# Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8,089 patients

23

Olympe Chazara<sup>1</sup>, Marie-Pierre Dubé<sup>2,3,4</sup>, Quanli Wang<sup>1</sup>, Lawrence Middleton<sup>1</sup>, Dimitrios Vitsios<sup>1</sup>,
Anna Walentinsson<sup>5</sup>, Qing-Dong Wang<sup>6</sup>, Kenny M. Hansson<sup>6</sup>, Christopher B. Granger<sup>7</sup>, John
Kjekshus<sup>8</sup>, Carolina Haefliger<sup>1</sup>, Jean-Claude Tardif<sup>2,3</sup>, Dirk S. Paul<sup>\*1</sup> and Keren Carss<sup>\*1</sup>

7

8 <sup>1</sup>Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; <sup>2</sup>Montreal 9 Heart Institute, Montreal, Canada; <sup>3</sup>Université de Montréal, Faculty of Medicine, Department of Medicine, Université de 10 Montréal, Montreal, Canada; <sup>4</sup>Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada; 11 <sup>5</sup>Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism 12 (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; <sup>6</sup>Bioscience Cardiovascular, Research and Early 13 Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 14 Sweden; <sup>7</sup>Duke Clinical Research Institute, Duke University, Durham, North Carolina; <sup>8</sup>Department of Cardiology, 15 University of Oslo, Oslo, Norway; \*These authors contributed equally.

16 Correspondence: Dirk S. Paul, dirk.paul@astrazeneca.com

- 17
- 18

## 19 Abstract

20

21 Most therapeutic development is targeted at slowing disease progression, often long after the initiating 22 events of disease incidence. Heart failure is a chronic, life-threatening disease and the most common 23 reason for hospital admission in people over 65 years of age. Genetic factors that influence heart 24 failure progression have not yet been identified. We performed an exome-wide association study in 25 8,089 patients with heart failure across two clinical trials, CHARM and CORONA, and one 26 population-based cohort, the UK Biobank. We assessed the genetic determinants of the outcomes 27 'time to cardiovascular death' and 'time to cardiovascular death and/or hospitalisation', identifying 28 seven independent exome-wide-significant associated genes, FAM221A, CUTC, IFIT5, STIMATE, 29 TAS2R20, CALB2 and BLK. Leveraging public genomic data resources, transcriptomic and pathway 30 analyses, as well as a machine-learning approach, we annotated and prioritised the identified genes for 31 further target validation experiments. Together, these findings advance our understanding of the 32 molecular underpinnings of heart failure progression and reveal putative new candidate therapeutic 33 targets.

Chazara et al.

## 35 Introduction

36

Heart failure is a common, chronic health condition with increasing prevalence. In 2017, an estimated 64.3 million people worldwide were living with heart failure<sup>1</sup>. Around 2% of adults have heart failure and, in those over the age of 65, the prevalence increases to  $6-10\%^{2-5}$ . Although survival after diagnosis has improved, death rates remain high, with 5-year survival averaging 50%<sup>6</sup>. Heart failure is the leading cause of both hospitalization and readmission amongst older adults<sup>7-9</sup>.

Studies have estimated the heritability of heart failure at 26%<sup>10</sup>. Genome-wide association studies 42 (GWAS) have characterised the contribution of common genetic variants to the aetiology of heart 43 failure<sup>11-13</sup>. We recently described the distinct contribution of rare genetic variation to all-cause heart 44 failure in a case-control study<sup>14</sup>. We also investigate the genetic differences between heart failure 45 46 subtypes based on left ventricular ejection fraction (LVEF) and the burden of Mendelian 47 cardiomyopathy variants in these patients. We observed an enrichment of variants typically associated 48 with dilated cardiomyopathy in patients with ischemic heart failure, in particular, protein-truncating 49 variants in the TTN gene. Our data supported the notion that genes linked to Mendelian 50 cardiomyopathy could represent therapeutic targets for a broader heart failure indication. Collectively, 51 the vast majority of genetic studies for common chronic diseases such as heart failure have informed 52 on disease incidence, with an unclear relationship to disease progression.

53 Most therapeutic development is targeted at slowing or arresting disease progression in individuals 54 who already have disease. However, studies of disease progression remain challenging, as they require 55 extensive, longitudinal clinical data that require expert curation, such as diagnoses, hospitalisation 56 dates, causes of hospitalisation and death. They also present statistical and computational challenges, as the most well-known approach for analysis of survival (or time-to-event) analysis, the Cox 57 proportional hazards model<sup>15</sup>, does not scale well to large datasets<sup>16</sup>. Partially overcoming these 58 challenges, powerful and efficient time-to-event analysis frameworks have recently been applied to the 59 UK Biobank<sup>17-19</sup>. For heart failure, these studies have mostly focused on time-to-diagnosis phenotypes 60 and/or considered only common genetic variants<sup>20</sup>. 61

62 The aim of this study was to identify rare variants associated with heart failure progression. Rare variants have typically larger effects on phenotypes and reveal more direct insights into biology that 63 can be exploited for medicine development<sup>21</sup>. Specifically, the objectives of this study were to (1) 64 65 perform a survival analysis of heart failure patients to identify genes with an excess or depletion of 66 rare variants in individuals with a detrimental outcome such as shorter time to cardiovascular death; 67 (2) explore how these results can inform the genetic architecture of heart failure progression; and (3) 68 evaluate which of the identified progression-associated candidate genes could present potential candidates for therapeutic development. To address these objectives, we analysed whole-exome 69 70 sequencing data from patients with heart failure, representing all broad clinical subtypes, from the 71 Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) and

#### Chazara et al.

Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) clinical trials, and heart failure patients from the UK Biobank<sup>22-24</sup>. All three cohort studies had extensive clinical information available and had been previously studied for heart failure incidence. We applied gene-based collapsing analyses within each study, followed by meta-analysis to discover genes with an excess of rare variants associated with two heart failure outcomes, 'time to cardiovascular death' and 'time to cardiovascular death and/or hospitalisation'.

- 78
- 79

80 Results

81

**Description of the study cohorts and analytical approach.** In this study, we analysed a total of 8,089 heart failure patients: 2,672 from CHARM, 2,776 from CORONA and 2,641 from the UK Biobank. From these 8,089 individuals, 1,328 (16.4%) died of cardiovascular death, and 2,451 (30.3%) either died of cardiovascular death or were hospitalised due to heart failure following study 86 entry (**Table 1, Figure 1**).

87 First, we analysed the three study cohorts separately to detect rare variants associated with the two 88 outcomes 'time to cardiovascular death' and 'time to cardiovascular death and/or heart failure 89 hospitalisation'. We used gene-level collapsing analyses to classify the genotypes, and Cox 90 proportional hazards regression with Firth's penalized likelihood to analyse each individual's disease 91 progression (Methods). In gene-level collapsing analyses, the proportion of cases with a qualifying 92 variant is compared with the proportion of controls with a qualifying variant in each gene. We applied 93 ten different sets of qualifying variant filters (models) (Methods). Finally, we used a meta-analysis 94 approach to identify genes with overall evidence of association.

95

96 Rare-variant analysis for time to cardiovascular death in heart failure patients. For time to 97 cardiovascular death in heart failure patients, the gene-based collapsing meta-analysis identified five significantly associated genes (p<2x10<sup>-7</sup>): FAM221A (p=3.85x10<sup>-8</sup>, hazard ratio (HR) 5.14), CUTC 98  $(p=3.90 \times 10^{-8}, HR 5.13), IFIT5 (p=4.77 \times 10^{-8}, HR 4.77), STIMATE (p=7.68 \times 10^{-8}, HR 4.39) and$ 99 TAS2R20 (p=2.57x10<sup>-7</sup>, HR 3.93) (Table 2, Figure 2A-E). The meta-analysis for these five genes was 100 101 based on the survival analysis of the three contributing studies, with at least five carriers per study. 102 None of the single-study analysis results for time to cardiovascular death in heart failure patients passed the significance threshold of  $p < 2x10^{-7}$ , demonstrating the power of meta-analysis for this 103 104 phenotype to discover novel rare-variant based signals (Supplementary Tables 1-3). The meta-105 analysis also revealed a significant association for CHRNA9 ( $p=1.89 \times 10^{-7}$ , HR 4.72) but the supporting 106 survival analysis in CHARM was violating the proportionality hazard assumption; therefore, we did 107 not report this association result.

Chazara et al.

We assessed the distributions of the qualifying variants along the length of each of the five identified genes (**Figure 3A-E**). We found that the observed associations with the lowest p-values were driven by at least eight variants per gene, and were evenly distributed across the length of the gene sequence (**Supplementary Table 4**).

112

113 Rare-variant analysis for the composite of time to cardiovascular death and/or heart failure 114 hospitalisation. For the second of the two outcomes investigates, the composite of time to 115 cardiovascular death and/or heart failure hospitalisation, the gene-based collapsing meta-analysis identified two significantly associated genes ( $p < 2x10^{-7}$ ): CALB2 ( $p = 4.82x10^{-9}$ , HR 4.47) and BLK 116 (p=5.46x10<sup>-8</sup>, HR 6.91) (**Table 2, Figure 2F-G**). While the meta-analysis for *CALB2* result was based 117 118 on the survival analysis of the three studies, with at least five carriers per study, the result for BLK was 119 only based on the CORONA and UK Biobank studies, as there was only one carrier for BLK in 120 CHARM. The proportionality hazard assumption was not met for CALB2 in CHARM, but after removal of the study from the analysis, the meta-analysis result remained significant ( $p=2.15 \times 10^{-8}$ . HR 121 122 5.48).

We report one significant result from the single-study analysis for time to cardiovascular death and/or heart failure hospitalisation in heart failure patients: RAD54L in the flexible non-synonymous model in CHARM (p=6.64x10<sup>-8</sup>, HR 3.96; **Supplementary Tables 5-7**). RAD54L in the corresponding analysis in CORONA and the UK Biobank was not significantly associated with heart failure progression (p>0.1 and number of qualifying variant carriers >30 in both cohorts). Different genetic architecture across the studies could reflect underlying clinical differences, due to the differing recruitment criteria employed.

We assessed the distributions of the qualifying variants along the length of the identified genes (Figure 3F-G) and found that the observed associations with the lowest p-values were driven by 13 variants for the *CALB2* gene and seven variants for *BLK* (Supplementary Table 4). We found these variants to be evenly distributed across the length of the gene sequence (Supplementary Table 4).

134

Orthogonal genetic evidence in support of rare-variant meta-analysis results. To investigate to what extent the discovered genes from our rare-variant meta-analyses are associated with related phenotypes in complementary data sources, we annotated the genes with orthogonal genetic evidence: (1) curated common-variant association studies for cardiovascular diseases from the Cardiovascular Disease Knowledge Portal (<u>https://cvd.hugeamp.org/</u>); (2) known Mendelian cardiomyopathy-causing genes; and (3) a gene prioritisation method that leverages external data sources using a machinelearning (ML) approach (Mantis-ML)<sup>25</sup>.

We collated the curated evidence from published GWAS from the Cardiovascular Disease
Knowledge Portal for the seven candidate genes from the meta-analysis for both tested outcomes
(Table 3). We found genome-wide significant associations with cardiovascular traits in the genomic

#### Chazara et al.

regions of CUTC, IFIT5, STIMATE, CALB2 and BLK. There were also genome-wide significant 145 146 associations with lipids traits in the regions of CUTC, STIMATE, CALB2 and BLK, and with 147 anthropometric traits in the regions of FAM211A, CUTC, STIMATE, CALB2 and BLK (Table 3A). A 148 limitation of this comparison is that a majority of the reported associations had the UK Biobank 149 included in the meta-analysis, and the relationship between the GWAS index variants and causal genes 150 at the loci requires further experimental confirmation. However, we did not detect genome-wide 151 significant associations in either the region or the gene for the most relevant reported phenotypes, i.e., 152 heart failure, non-ischemic cardiomyopathy, atrial fibrillation, any cardiovascular disease, myocardial 153 infarction, and hypertension. Only IFIT5, STIMATE and CALB2 had suggestive associations (p<1x10<sup>-</sup> 154 <sup>5</sup>) for any cardiovascular disease (IFIT5 and STIMATE) or hypertension (STIMATE and CALB2) 155 (Table 3B). The lowest p-values observed in the CUTC region were for heart rate  $(p=2.73 \times 10^{-9})$ , 156 height ( $p=1.80 \times 10^{-28}$ ) and atrial fibrillation ( $p=1.79 \times 10^{-4}$ ) (**Table 3B**). 157 Among the known rare or low-frequency variants in cardiomyopathy-causing genes previously

identified such as *TTN*, *MYH7* and *MYBPC3* for heart failure incidence and *LMNA* and *LAMP2* for heart failure progression, we observed a non-significant association of ultra-rare variants in *MYBPC3* with time to cardiovascular death ( $p=2.05 \times 10^{-6}$ , HR 4.38), but not for the other reported genes. Most of these cardiomyopathy-causing genes had a very low number of pathogenic variant carriers, making interpretation challenging. However, *TTN* pathogenic variants were more frequent, indicating that *TTN* might be specifically associated with heart failure incidence rather than progression, which has been reported previously<sup>26</sup>.

165 Finally, we applied Mantis-ml, a ML framework leveraging publicly available gene annotation data to prioritise disease-gene associations<sup>25</sup>. We used this orthogonal method to investigate the extent to 166 which the significant genes from our rare-variant meta-analyses (p<0.01) are similar to genes known, 167 168 or predicted with high confidence, to be associated with relevant phenotypes (i.e., the top-ranked 169 genes from Mantis-ml conditioned on heart failure or cardiomyopathy). These similarities were 170 quantified using a step-wise hypergeometric test (Methods). For both outcomes, we found the overlap 171 in relevant phenotypes to be greater for the qualifying variant models that capture functional variants 172 than for the synonymous negative control model (Supplementary Figs. 1A, 1B). In addition, 173 collapsing the 33 heart failure/cardiomyopathy disease classes available to a single metric (i.e., taking 174 either the maximum or the AUC), we found significantly superior performance of the pooled qualifying variant model compared to the synonymous model for both, time to cardiovascular death 175  $(p_{max}=1.6x10^{-5} \text{ and } p_{AUC}=8.0 x10^{-4})$  and time to cardiovascular death and/or hospitalisation for heart 176 failure ( $p_{max}=5.1x10^{-5}$  and  $p_{AUC}=3.9x10^{-4}$ ) (Supplementary Fig. 1C). Taken together, these results 177 showed that the features of the most significantly associated genes from our meta-analysis share 178 179 similarities with the features of genes already known, or strongly predicted, to be associated with 180 relevant phenotypes, supporting our genetic data.

#### Chazara et al.

Expression analysis in heart tissues aids gene prioritisation for further validation. Next, we assessed the expression patterns of the candidate causal genes underlying the genetic associations for heart failure progression. Normalized gene expression data collected by the GTEx Project<sup>27</sup> were interrogated for the seven candidates genes from the meta-analysis for both tested outcomes (**Table 2**). We used the 54 different tissues sampled by GTEx as well as a subset of 16 cardiovascular tissues.

The overall tissue expression analysis revealed that *CUTC*, *STIMATE* and *IFIT5* are expressed in almost all tissues analysed; *CALB2* and *BLK* are expressed in multiple tissues but not all; and *TAS2R20* and *FAM221A* have comparatively low expression across all tissues analysed (**Supplementary Fig. 2A**). *CUTC* was the gene most strongly expressed in the heart. In cardiovascular tissue, a similar gene grouping was observed, with *CUTC* highest in skeletal muscle, *CALB2* in adipose, and *BLK* in whole blood and spleen tissues (**Supplementary Fig. 2B**).

193 Next, we analysed differential expression of the candidate genes in tissues from ventricular 194 myocardial biopsies in heart failure with preserved/reduced ejection fraction (HFpEF/HFrEF), 195 (idiopathic) dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), ischemic 196 cardiomyopathy (ICM), and controls from three separate public transcriptomics studies (Figure 4, 197 Supplementary Table 8<sup>28</sup>. CUTC, IFIT5, TAS2R20, FAM221A and BLK showed significant differential expression between the healthy and diseased heart. Among these, CUTC was most 198 199 consistently dysregulated, being downregulated across studies and heart failure aetiologies. TAS2R20 200 and BLK have low expression in the heart, making the results challenging to interpret. FAM221A, 201 IFIT5 and TAS2R20 showed significant differential expression between HFpEF vs HFrEF patients in 202 the right ventricle (Figure 4, Supplementary Fig. 2, Supplementary Table 8).

Taken together, based on all transcriptional datasets, we highlight *CUTC* as a potential therapeutic target for heart failure progression that warrants further experimental validation and assessment.

205

206 Functional enrichment analysis identifies molecular functions and pathways of candidate genes.

To identify potential molecular functions and pathways underlying the genetic associations, we performed a gene ontology analysis of the candidate genes. We tested 1298 unique genes ranked by their lowest fixed model p-value across the ten non-synonymous collapsing analysis models from the time to cardiovascular death meta-analysis. We found enrichment (adjusted p<0.05) for the following molecular functions: adenyl ribonucleotide binding (GO:0032559, p=8.91x10<sup>-4</sup>); adenyl nucleotide binding (GO:0030554, p=1.43x10<sup>-3</sup>); lamin binding (GO:0005521, p=1.49x10<sup>-3</sup>); among others

213 (Supplementary Fig. 3A, Supplementary Table 9).

We also performed the analysis for the 956 unique genes from the time to cardiovascular death and/or hospitalisation for heart failure meta-analysis. This analysis revealed enrichment for the following molecular functions and biological pathways: ion binding (GO:0043167, p= $3.42 \times 10^{-3}$ ); glycine, serine and threonine metabolism (KEGG:00260, p= $4.17 \times 10^{-3}$ ); among others (Supplementary Fig. 3B, Supplementary Table 9).

Chazara et al.

219

## 220 Discussion

221

The identification of determinants of disease progression is critical for drug development, as most clinical trials assess the efficacy and safety of treatments that slow or arrest disease progression in patients with disease or prevent secondary events in specific patient groups. However, in contrast to the relatively large number of genetic studies on the incidence of common chronic diseases, including heart failure, there are few published studies investigating the genetic basis of disease progression.

227 In our study, we implemented a survival analysis for rare variants based on collapsing analysis and 228 Cox proportional hazards regression with Firth's penalized likelihood. We analysed the whole-exome 229 sequencing data of 8,089 heart failure patients from three clinically well-defined studies: two clinical 230 trials, CHARM and CORONA, and one population-based study: the UK Biobank. We performed 231 meta-analysis and reported results found in at least two studies and supported by at least five carriers 232 per study. We report seven genes not previously associated with heart failure progression with hazard 233 ratios between 3.93 and 6.91. Specifically, we identified five candidate genes for cardiovascular death 234 risk in heart failure patients: FAM221A, CUTC, IFIT5, STIMATE and TAS2R20, and two candidate 235 genes for the composite of cardiovascular death and/or heart failure hospitalisation risk in heart failure 236 patients: CALB2 and BLK.

Importantly, none of these identified candidate gene loci have previously been associated with heart incidence through common-variant association studies, suggesting distinct genetic aetiology for heart failure progression compared to incidence. However, when evaluating the prior evidence of association with disease incidence, we found that all but two candidate gene loci (i.e., *FAM221A* and *TAS2R20*) harboured genome-wide significant, common-variant associations with cardiovascular traits, including heart rate, ascending aorta diameter and blood pressure.

We showed that several of the candidate genes are expressed in relevant cardiovascular tissues. In particular, *CUTC* is expressed strongly in heart tissues. Using heart single-cell RNA-seq data, we demonstrated that *CUTC* is expressed by all cardiac cell types with highest fractional expression in cardiomyocytes (**Supplementary Fig. 4**). Further, we demonstrated differential expression of five out of seven candidate genes between diseased and healthy hearts and/or between heart failure subtypes.

Finally, ML-based enrichment analysis supported our gene ranking from the meta-analysis, especially for the cardiovascular death outcome, as indicated by step-wise hypergeometric analyses. Functional enrichment analysis highlighted known pathways in cardiovascular disease, such as lamin binding (enrichment supported by *SUN1*, *TMEM201*, *SUN2*, *SYNE1* and *PLCB1*), and novel pathways,

such as glycine, serine and threonine metabolism (supported by *GLDC*, *PGAM1* and *ALDH7A1*)<sup>29,30</sup>.

253 CUTC was the only gene that showed an association with both tested endpoints, as well as strong 254 expression in the heart and differential expression between diseased and healthy heart tissues. CUTC 255 encodes a member of the CUT family of copper transporters that are associated with copper

### Chazara et al.

homeostasis and involved in the uptake, storage, delivery and efflux of copper<sup>31-33</sup>. Defective copper 256 257 metabolism has been linked to various cardiovascular diseases, including heart failure. Mutations in 258 genes encoding copper chaperones/transporters associate with cardiac disease in humans and mice<sup>34</sup>. 259 Notably, the ongoing TRACER-HF trial (NCT03875183) evaluates the effects of a copper-binding 260 agent INL1 in patients with HFrEF. INL1 is hypothesized to redistribute copper from high-261 concentration gradient (e.g., the circulation) to copper-depleted tissues (e.g., ischemic myocardial 262 tissue), inducing heart regeneration. Although the exact function of CUTC remains to be determined, 263 it has been suggested that it might act as an enzyme with Cu(I) as a cofactor rather than a copper 264 transporter<sup>31</sup>. Moreover, CUTC participates in cardiac conduction and ion channel transport pathways 265 based on the PathCards database (https://pathcards.genecards.org) and our co-expression network 266 analysis suggested a role in muscle physiology and mitochondrial function (Supplementary Fig. 4). 267 These pathways are all highly relevant biofunctions in heart failure pathophysiology. Our tractability 268 assessment further revealed that CUTC contains a high-quality ligand pocket and is predicted 269 druggable using small molecules (Supplementary Table 10). Taken together, CUTC may represent 270 an attractive new candidate therapeutic target in heart failure.

Of note, alternative *CUTC* transcripts overlap *COX15*, encoding the Cytochrome C Oxidase Assembly Homolog. Despite a larger number of rare variant carriers than *CUTC*, *COX15* was not significantly associated with either cardiovascular death or the composite of cardiovascular death and/or heart failure hospitalisation in our analyses (**Supplementary Tables 11, 12**). Diseases associated with *COX15* include Mitochondrial Complex IV Deficiency, Nuclear Type 6 and Fatal Infantile Cardioencephalomyopathy Due To Cytochrome C Oxidase Deficiency. It has been proposed that *CUTC* and *COX15* functions in partnership as they share a bidirectional promoter<sup>35</sup>.

278 STIMATE and CALB2 are involved in calcium binding, signalling or channel activity. Calcium pathways are fundamental for electrical signalling in the heart<sup>36</sup>. Several known mechanisms of 279 cardiac pathologies are underlined by calcium channels<sup>36</sup>. A major class of drug targets already exist 280 for calcium channel regulation<sup>37,38</sup>. Calcium antagonists have been used to treat ischemia, a common 281 282 cause of heart failure<sup>39</sup>. IFIT5 and BLK, are involved in immune system function. It is established that 283 inflammation plays an important role in chronic heart failure, after myocardial infarction or other 284 myocardial damage, and heart failure is associated with circulating inflammatory cytokines that can 285 predict clinical outcomes<sup>40</sup>. Whether inflammation plays a causal role remains to be established<sup>41</sup>. A number of taste receptors including TAS2R20 are expressed in human heart and the role of these 286 287 receptor in cardiac physiology and pathophysiology is not well understood yet<sup>42</sup>. It is notable that 288 TAS2R20 RNA expression is significantly increased in the myocardium in HFpEF patients but not in 289 HFrEF patients, suggesting that TAS2R20 may have a specific role in HFpEF.

In our meta-analysis, we did not discover any significantly associated protective genes. Such genes would be particularly promising for drug development as a protective effect of loss of function mimics the therapeutic inhibition of a drug. We observed previously in genetic analyses of heart failure

#### Chazara et al.

293 incidence that detrimental association of rare variants are more prevalent than protective associations,

294 because they are enriched for loss-of-function variants<sup>14</sup>.

295 We acknowledge that our study had limitations. Due to the paucity of exome-wide investigation of 296 the role of rare variants in heart failure progression, we were currently unable to replicate our findings 297 in an independent study cohort. More collaborative research is needed to address this limitation of our 298 study, e.g., through the HERMES consortium that aims to assess the contribution of common genetic variants to heart failure progression<sup>20</sup>. Further, we note that the definition of heart failure amongst the 299 300 cases was heterogeneous, for example, with respect to the presence or absence of cardiomyopathy, and 301 different LVEF categories (HFrEF vs HFpEF). Due to the study of rare variants, stratifying patients 302 according to phenotypic subtypes would have substantially reduced power. Additionally, for heart 303 failure incidence and cardiomyopathy-associated rare variants, we previously detected some overlapping genetic architecture between heart failure subtypes<sup>14</sup>, supporting our combined approach 304 305 in this study. Future larger studies would facilitate stratified analyses. Finally, our study focussed on 306 individuals of European ancestry because there are insufficient numbers of patients of other ancestries. 307 Further studies are needed to replicate our findings in other ancestry groups. 308 In conclusion, by rare-variant collapsing meta-analysis, we have identified seven candidate genes 309 significantly associated with heart failure progression: FAM221A, CUTC, IFIT5, STIMATE, TAS2R20, 310 CALB2 and BLK. Pending replication, several of these genes could represent promising drug targets

311 for heart failure, as supported by their tissue expression and function.

Chazara et al.

## 313 Methods

314

**Ethics statement.** Sites participating in the CHARM and CORONA studies received approval from local ethics committees for their conduct<sup>22,23</sup>. Only patients who gave written informed consent for genetic analysis and for whom a DNA sample was available were included in the present study. The present study was performed in accordance with the policies on bioethics and human biologic samples of AstraZeneca. The protocols for UK Biobank are overseen by the UK Biobank Ethics Advisory Committee. For more information see <u>https://www.ukbiobank.ac.uk/ethics/</u>.

321

322 CHARM and CORONA studies. The CHARM programme enrolled heart failure patients of >18 323 years of age into three distinct trials and randomly assigned them to receive candesartan or placebo: 324 patients with LVEF >40% (CHARM Preserved; NCT00634712); patients with LVEF  $\leq$  40% and 325 treated with angiotensin converting enzyme inhibitor (CHARM Added; NCT00634309); and patients 326 with LVEF  $\leq 40\%$  and intolerant to angiotensin-converting enzyme inhibitor treatment (CHARM Alternative; NCT00634400)<sup>22</sup>. In the CHARM study, heart failure cause could be defined as ischemic, 327 idiopathic, hypertensive or other causes<sup>22</sup>. The CORONA study enrolled patients of >60 years of age 328 329 with chronic heart failure of ischemic cause and a LVEF  $\leq 40\%$  and randomly assigned them to receive rosuvastatin or placebo (NCT00206310)<sup>23</sup>. An overview of the patient characteristics of the 330 331 trials is provided in Table 1.

332 In the CHARM and CORONA trials, the same two endpoints (i.e., cardiovascular death and a 333 composite of cardiovascular death and/or heart failure hospitalisation) were defined by the clinical 334 teams. For CHARM, cardiovascular death or unplanned admission to hospital for the management of 335 worsening congestive heart failure was the primary outcome for the trial. All deaths were classified as 336 cardiovascular unless an unequivocal non-cardiovascular cause was established. An heart failure 337 hospital admission was defined as an admission to hospital because of heart failure with evidence of 338 worsening heart failure<sup>22</sup>. For CORONA, the primary outcome was death from cardiovascular causes, 339 nonfatal myocardial infarction, or nonfatal stroke. Deaths were classified as due to cardiovascular 340 causes unless a definite non-cardiovascular reason was identified. Hospitalization for heart failure 341 required documentation that worsening heart failure was the principal reason for hospitalization<sup>23</sup>.

342

343 **UK Biobank.** The UK Biobank is a large prospective cohort study with 500,000 participants aged 40 344 to 69 years recruited from the general population in the United Kingdom<sup>24</sup>. The UK Biobank ICD10 345 codes (International Statistical Classification of Diseases and Related Health Problems, Tenth 346 Revision codes) were interrogated for the following heart failure phenotypes: I11.0, I13.0, I13.2, 347 I25.5, I42.0, I42.5, I42.8, I42.9 and I50.x<sup>11</sup>. Overall, 11,076 individuals with at least one primary or 348 secondary hospital in-patient diagnoses code (Data-Field ID 41270), and/or at least one underlying 349 (primary) cause of death in the death register (Data-Field ID 40001) in those categories, were

#### Chazara et al.

considered as heart failure patients. In order to more closely match a clinical study design, only cases with heart failure diagnosis codes dated prior to recruitment were included in the analyses. Measurements of LVEF were not performed for the UK Biobank patients, as it was only available for a small number of individuals randomly selected from the biobank (**Table 1**).

354 For our analysis, we defined two endpoints: cardiovascular death (CVD) and a composite of 355 cardiovascular death and/or heart failure hospitalisation (CVD HFHOSP). In the UK Biobank, 356 cardiovascular death was defined as a primary cause of death (Data-Field ID 40001) with any ICD10 357 codes in the Chapter IX (Diseases of the circulatory system), which correspond to I00-I99 codes. 358 Heart failure hospitalisation was defined as a hospitalisation at least 28 days after the first diagnosis, 359 with the same code used for the heart failure patient definition. To match the modelling approach used 360 in the clinical studies, the date of recruitment was used to calculate the time to event. The end of 361 follow-up was considered to be the date of the last major UK Biobank update (01/09/2019).

362

363 Exome-sequencing. For CHARM, CORONA and UK Biobank, exomes were captured with the IDT 364 xGen Exome Research Panel V1.0 (Integrated DNA Technologies, Coralville, IA, USA) and 365 sequenced according to standard protocols on Illumina's NovaSeq 6000 (Illumina, San Diego, CA, 366 USA) platform. Exome sequencing for CHARM and CORONA was performed using 150bp pairedend reads at the Institute for Genomic Medicine at the Columbia University Medical Center, as 367 368 previously described<sup>14</sup>. Exome sequencing for the UK Biobank using 75-bp paired-end reads and 369 initial sample-level QC the UK Biobank was performed at Regeneron Pharmaceuticals, as previously described<sup>14,43,44</sup>. Quality control of the genetic data performed by Regeneron included sex discordance, 370 371 contamination, unresolved duplicated sequences and discordance with microarray genotyping data<sup>45</sup>.

372 Sequence data from all three studies was processed through the AstraZeneca's Centre for 373 Genomics Research bioinformatics pipeline using a custom-built Amazon Web Services cloud 374 compute platform running Illumina DRAGEN Bio-IT Platform Germline Pipeline v3.0.7. The reads 375 were aligned to the GRCh38 genome reference, followed by single-nucleotide variant (SNV) and indel 376 calling. SNVs and indels were first annotated using SnpEFF v4.34 against Ensembl Build 38.92. 377 Variants were then annotated using the Genome Aggregation Database (gnomAD) minor allele 378 frequencies (gnomAD v2.1.1 mapped to GRCh38), missense tolerance ratio (MTR) and REVEL scores<sup>46-48</sup>. 379

380

Sample and variant quality control (QC). The pre-QC dataset consisted of 3,090 CHARM, 2,906 CORONA and 2,868 UK Biobank participants. The following samples were removed: discordance between self-reported sex and genomic predicted sex based on X:Y coverage ratio; >4% contamination according to VerifyBamID v1.0.5; <95% of CCDS (release 22) bases covered with at least 10-fold coverage; related (up to third degree with KING v2.2.3), probability of European Ancestry <0.98 (<0.99 for UK Biobank) based on PEDDY v0.4.2 predictions; and individuals within

Chazara et al.

four standard deviations of principal components 1-4 (Supplementary Table 13)<sup>49-51</sup>. The final
filtered dataset for analysis consisted of 2,672 CHARM, 2,776 CORONA and 2,641 UK Biobank
samples (Figure 1, Table 1).

390

391 **Gene-level collapsing analyses.** We first performed, in the three cohorts separately, gene-based 392 collapsing analyses to identify patients carrying at least one qualifying variant in each protein-coding 393 gene. A qualifying variant is defined as a variant that passes certain filter criteria specific to each 394 genetic model. **Supplementary Table 14** summarises the genetic models used for the analyses. We 395 analysed ten non-synonymous models (nine of which are dominant and one recessive), plus an 396 additional synonymous variant model as a negative control<sup>52</sup>.

397 The data was modelled using Cox proportional hazards regression with Firth's penalized 398 likelihood, which provides a solution to the non-convergence of the likelihood function, more frequently observed with rare-variant analysis: coxphf<sup>53,54</sup>. Genotypes were encoded as binary variable 399 400 after the first step of collapsing analysis. The coxphf method has been shown to be appropriate for 401 genome-wide time-to-event analysis, both in terms of controlling type I error rates, and power for 402 variants with low minor allele frequency<sup>18</sup>. In CHARM and CORONA, age at recruitment, sex and treatment arm were used as covariates in all analyses. The coxphf default of confidence intervals and 403 404 tests based on the profile penalized log likelihood was used. In the UK Biobank, age at recruitment 405 (Data-Field ID 21022) and sex (Data-Field 22001) were used as covariates in all analyses. For the 406 collapsing survival analysis, the Bonferroni multiplicity adjusted threshold was set at  $p=2.7 \times 10^{-7}$  ( $\alpha =$ 407 [0.05 / (18,500 genes \* 10 non-synonymous models)]). This threshold was supported by permuting the 408 data using R perm function (n=1) within the synonymous model, comparing with observed p-values 409 with quantile-quantile plots and estimating the genomic inflation factor  $\lambda$  (Supplementary Fig. 5). 410 The proportionality of hazards assumption was examined for the top genes by using the Schoenfeld 411 residuals against the transformed time.

412

413 Meta-analysis. We conducted a meta-analysis using PLINK v1.90 on the beta-values and standard 414 errors extracted from the coxphf results. We computed both fixed and random effect meta-analysis 415 models, and we only reported results supported by at least five carriers in each study. We computed 416 both fixed and random effects meta-analysis models and reported random effects results with a 417 heterogeneity index I<sup>2</sup>>40. Consistent with the survival analysis, the meta-analysis Bonferroni 418 multiplicity adjusted threshold was set at  $p < 2.7 \times 10^{-7}$  ( $\alpha = [0.05 / (18,500 \text{ genes } * 10 \text{ non-synonymous})$ 419 models)]). Quantile-quantile plots for the meta-analysis were generated with (permutation-based) 420 expected p-values from data permuted prior to the collapsing survival analysis using the R perm 421 function (n=1) (Supplementary Figs. 6A, 6B).

#### Chazara et al.

423 Sensitivity analysis. Analyses were conducted with additional covariates such as BMI and prior 424 diabetes to assess the robustness of results when relevant for the genes with significant results 425  $(p<2.7x10^{-7})$  in the meta-analysis of CHARM, CORONA and the UK Biobank for both tested 426 outcomes. Detailed clinical information supporting the analyses are reported in Table 1. Sensitivity 427 analyses did not change the observed results (Supplementary Table 15).

428

429 **RNA expression.** We interrogated median TPM-normalized gene expression for 54 tissues sampled in 948 donors provided by GTEx  $v8^{27}$ . We defined a subset of 16 cardiovascular tissues as follows: 430 431 Adipose - Subcutaneous, Adipose - Visceral (Omentum), Adrenal Gland, Artery - Aorta, Artery -432 Coronary, Artery - Tibial, Heart - Atrial Appendage, Heart - Left Ventricle, Kidney - Cortex, Kidney -433 Medulla, Liver, Muscle - Skeletal, Pancreas, Spleen, Thyroid, Whole Blood. 434 In addition, we extracted and analysed data from three published myocardial transcriptomic 435 analyses: (1) HFpEF (n=41), HFrEF (n=30) and controls (n=24); (2) DCM (n=166), HCM (n=28) and 436 (n=166) (GSE141910, The controls Myocardial Applied Genomics Network; 437 https://www.med.upenn.edu/magnet/); and (3) idiopathic DCM (n=82), ICM (n=95) and controls

- 438  $(n=136) (GSE57338)^{55}$ .
- 439

440 Annotation with GWAS data. For the genes most significantly associated with heart failure 441 progression, we compiled genetic evidence from the curated GWAS results of external studies 442 available in the Cardiovascular Disease Knowledge Portal (https://cvd.hugeamp.org/). First, we listed 443 the association with the lowest genome-wide significant p-values in the region, where associations are 444 clumped by linkage disequilibrium and classified into three phenotypes group: cardiovascular, lipids 445 and anthropometric. Then, we used the Cardiovascular Disease Knowledge Portal Genomic Region 446 Miner tool to extract the lowest variant associations across each region or in the gene for the following 447 six phenotypes: heart failure, non-ischemic cardiomyopathy, atrial fibrillation, any cardiovascular 448 disease, myocardial infarction, or hypertension.

449

450 **Step-wise hypergeometric enrichment analysis with Mantis-ml.** Mantis-ml is a method for gene 451 prioritisation, leveraging publicly available gene annotation data from multiple resources to derive 452 genetic association scores for a user-specified disease<sup>25</sup>. Harnessing data from resources such as 453 OMIM, ExAC, Essential Mouse Genes, GnomAD, MSigDB, GTEx and genic-intolerance scores 454 (RVIS and MTR) among others, we used this tool to assess to what extent the most significant genes 455 from the meta-analysis are similar to genes known to be associated with heart failure or 456 cardiomyopathy.

We performed a step-wise hypergeometric test between the study-ranked list of genes with a fixed p-value<0.01 for one of the outcomes (**Supplementary Tables 11, 12**) and 18,626 genes pre-ranked by their Mantis-ml association scores for 33 diseases containing either 'heart failure' or

460 'cardiomyopathy' (i.e., 26 from OpenTargets, four from HPO, three from Genomics England). An
461 overview of these diseases is provided in Supplementary Table 16. The resulting step-wise
462 hypergeometric curves are shown in Supplementary Fig. 1.

This test quantifies the overlap between the list of genes identify in this heart failure progression study and the list of genes ranked according to independent data sources by Mantis-ml. The p-values generated are converted to Phred scores. Enrichment performance were assessed and p-values obtained using the one-sided Mann-Whitney U test.

467

468 Gene ontology enrichment analysis. A functional enrichment analysis was performed using 469 g:Profiler for the same lists of genes ordered on fixed p-value as done for the annotation with Mantis-470 ml, i.e., the genes with a fixed effect p-value<0.01 for each of the outcomes (Supplementary Tables 11, 12)<sup>56</sup>. The data sources tested were Gene Ontology (GO, molecular function, cellular component, 471 472 biological process), KEGG and miRTarBase. The background set of gene used to compute the 473 functional enrichment was the 18,948 genes list from the Consensus Coding Sequence (CCDS, release 474 22), over annotated genes. Multiple testing correction for p-values was computed by applying the 475 default g:SCS method.

476

477 **Tractability assessment.** For the genes most significantly associated with heart failure progression, 478 we assessed the amenability to intervention by different drug modalities, including small molecules, 479 antibodies, PROTAC and others, using the Open Target Platform (https://platform.opentargets.org/). 480 The genes were categorized based on 'buckets' representing different levels of tractability, ranging from high confidence (lower number) to uncertain tractability (higher number), as previously 481 482 described<sup>57</sup>. In addition, genes were also classified according to their 'target development level' (TDL) 483 into either of four classes (i.e., Tclin, Tchem, Tbio or Tdark) using the Target Central Resource 484 Database (TCRD, http://juniper.health.unm.edu/tcrd/). In brief, Tclin are proteins through which 485 approved drugs act (i.e., mode-of-action drug targets); Tchem are proteins known to bind small 486 molecules with high potency; Tbio are proteins with well-studied biology, having a fractional 487 publication count above 5; and Tdark are understudied proteins that do not meet criteria for the above 488 3 categories, respectively (Supplementary Table 10).

489

490 Co-expression network analysis. To further explore the *CUTC* function, we performed co-expression
 491 analysis using GeneNetwork v2.0 (<u>https://www.genenetwork.nl/</u>), which predicts pathway and human
 492 phenotype associations using 31,499 public human RNA-seq samples (Supplementary Fig. 4).<sup>58</sup>

- 493
- 494

# 495 Data availability

497	Summa	ry statistics from the rare-variant collapsing analyses are available within the article and its										
498	Suppler	nentary Information files. Access to the UK Biobank data can be gained via the UK Biobank										
499	website	: <u>https://bbams.ndph.ox.ac.uk/ams/</u> .										
500												
501												
502	Code	availability										
502												
503	Saguar	as data ware recorded through a system built Amazon Wak Services aloud commute relatform										
504		the services croud compute platform										
505	running	g Illumina DRAGEN Bio-II Platform. SNVs and indels were annotated using SnpEFF v4.3										
506	against Ensembl v38.92. The software used in this study are referenced in the manuscript and are											
507	availab	le online: Mantis-ml ( <u>https://github.com/astrazeneca-cgr-publications/mantis-ml-release</u> ),										
508	QQperr	n (https://cran.r-project.org/web/packages/QQperm/index.html).										
509												
510												
511	Refere	nces										
512	1	GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, Global, regional, and										
513	1	national incidence, prevalence, and years lived with disability for 354 diseases and injuries for										
514		195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of										
515		Disease Study 2017. Lancet 392, 1789-1858 (2018).										
516	2	Metra, M. & Teerlink, J. R. Heart failure. Lancet 390, 1981-1995 (2017).										
517	3	McMurray, J. J. V. & Pfeffer, M. A. Heart failure. Lancet 365, 1877-1889 (2005).										
518	4	Dickstein, K. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart										
519		failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart										
520		Failure 2008 of the European Society of Cardiology. Developed in collaboration with the										
521		Heart Failure Association of the ESC (HFA) and endorsed by the European Society of										
522		Intensive Care Medicine (ESICM). Eur Heart J 29, 2388-2442 (2008).										
523	5	Cook, C., Cole, G., Asaria, P., Jabbour, R. & Francis, D. P. The annual global economic										
524		burden of heart failure. Int J Cardiol 171, 368-376 (2014).										
525	6	Savarese, G. & Lund, L. H. Global Public Health Burden of Heart Failure. Card Fail Rev 3, 7-										
526	_	11 (2017).										
527	7	Retrum, J. H. et al. Patient-identified factors related to heart failure readmissions. Circ										
528	0	Cardiovasc Qual Outcomes 6, 1/1-1/7 (2013).										
529	8	Roger, V. L. <i>et al.</i> Heart disease and stroke statistics2012 update: a report from the										
530	0	American Heart Association. Circulation 125, e2-e220 (2012).										
531	9	National Clinical Guideline Centre (UK). Chronic Heart Failure: National Clinical Guideline										
522		College of Dhysicians (LW) 2010)										
537	10	Lindgren M D at al A Swedish Nationwide Adoption Study of the Heritability of Heart										
535	10	Enlagren, M. 1. <i>et al.</i> A Swedish Nationwide Adoption Study of the Heritability of Heart Failure <i>IAMA cardiology</i> <b>3</b> , 703–710 (2018)										
536	11	Shah S <i>at al</i> Genome-wide association and Mendelian randomisation analysis provide										
537	11	insights into the pathogenesis of heart failure <i>Nature Communications</i> <b>11</b> 163 (2020)										
538	12	Arvanitis M <i>et al.</i> Genome-wide association and multi-omic analyses reveal ACTN2 as a										
539		gene linked to heart failure. <i>Nature Communications</i> 11, 1122 (2020).										
540	13	Joseph, J. <i>et al.</i> Genetic Architecture of Heart Failure with Preserved versus Reduced Election										
541	-	Fraction. medRxiv, 2021.2012.2001.21266829 (2021).										
542	14	Povysil, G. et al. Assessing the Role of Rare Genetic Variation in Patients With Heart Failure.										
543		JAMA Cardiol 6, 379-386 (2021).										

Unazara era.
--------------

544 545	15	Cox, D. R. Regression Models and Life-Tables. Journal of the Royal Statistical Society:
545	16	Series B (Methodological) 34, 187-202 (1972).
546 547	16	Xue, X. <i>et al.</i> Testing the proportional hazards assumption in case-cohort analysis. <i>BMC Med Res Methodol</i> <b>13</b> , 88 (2013).
548	17	Li, R. et al. Fast Lasso method for large-scale and ultrahigh-dimensional Cox model with
549		applications to UK Biobank. <i>Biostatistics</i> 23, 522-540 (2022).
550	18	Bi, W., Fritsche, L. G., Mukherjee, B., Kim, S. & Lee, S. A Fast and Accurate Method for
551		Genome-Wide Time-to-Event Data Analysis and Its Application to UK Biobank. American
552		Journal of Human Genetics 107, 222-233 (2020).
553	19	Legault, MA., Perreault, LP. L. & Dubé, MP. ExPheWas: a browser for gene-based
554		pheWAS associations. medRxiv, 2021.2003.2017.21253824 (2021).
555	20	Lumbers, R. T. et al. The genomics of heart failure: design and rationale of the HERMES
556		consortium. ESC Heart Fail 8, 5531-5541 (2021).
557	21	Povysil, G. et al. Rare-variant collapsing analyses for complex traits: guidelines and
558		applications. <i>Nat Rev Genet</i> <b>20</b> , 747-759 (2019).
559	22	Pfeffer, M. A. et al. Effects of candesartan on mortality and morbidity in patients with chronic
560		heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003).
561	23	Kjekshus, J. et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357,
562		2248-2261 (2007).
563	24	Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature
564		<b>562</b> , 203-209 (2018).
565	25	Vitsios, D. & Petrovski, S. Mantis-ml: Disease-Agnostic Gene Prioritization from High-
566		Throughput Genomic Screens by Stochastic Semi-supervised Learning. American Journal of
567		Human Genetics 106, 659-678 (2020).
568	26	Tobita, T. et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and
569		left ventricular reverse remodeling. Sci Rep 8, 1998 (2018).
570	27	Consortium, G. T. The GTEx Consortium atlas of genetic regulatory effects across human
571		tissues. Science <b>369</b> , 1318-1330 (2020).
572	28	Hahn, V. S. et al. Myocardial Gene Expression Signatures in Human Heart Failure With
573	20	Preserved Ejection Fraction. Circulation 143, 120-134 (2021).
574	29	Worman, H. J., Ostlund, C. & Wang, Y. Diseases of the nuclear envelope. <i>Cold Spring Harb</i>
575	20	Perspect Biol 2, a000/60 (2010).
576	30	wittemans, L. B. L. <i>et al.</i> Assessing the causal association of glycine with risk of cardio-
5//	21	Li V Dy L Zhang D & Ding L Crystal structure of hymon compar homosotosis motoin
570	51	Li, I., Du, J., Zhang, F. & Ding, J. Crystal structure of human copper homeostasis protein
580	22	Curto Iso P. T. Camakaria, J. & Wu, H. C. Identification of aut C. and aut E. (nln E).
581	32	Genes involved in conner tolerance in Escherichia coli <i>L Ractariol</i> <b>177</b> (207 A215 (1005)
582	33	Li L at al Identification and characterization of a novel Cut family cDNA that encodes
583	55	human conner transporter protein CutC <i>Biochem Biophys Res Commun</i> <b>337</b> 179-183 (2005)
584	34	Liu Y & Miao I An Emerging Role of Defective Conner Metabolism in Heart Disease
585	54	Nutrients 14 (2022)
586	35	Uchiumi, F., Fujikawa, M., Miyazaki, S. & Tanuma, Si, Implication of bidirectional
587		promoters containing duplicated GGAA motifs of mitochondrial function-associated genes.
588		AIMS Mol Sci 1, 1-26 (2014).
589	36	Berridge, M. J., Bootman, M. D. & Roderick, H. L. Calcium signalling: dynamics,
590		homeostasis and remodelling. Nat Rev Mol Cell Biol 4, 517-529 (2003).
591	37	Rinnier, R. T., Goldberg, M. E. & Torjman, M. C. in The Essence of Analgesia and Analgesics
592		(eds J. Michael Watkins-Pitchford, Jonathan S. Jahr, & Raymond S. Sinatra) 310-315
593		(Cambridge University Press, 2010).
594	38	Suckfüll, M. et al. A randomized, double-blind, placebo-controlled clinical trial to evaluate
595		the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus.
596		BMC Ear Nose Throat Disord 11, 1 (2011).
597	39	Sueta, D., Tabata, N. & Hokimoto, S. Clinical roles of calcium channel blockers in ischemic
598		heart diseases. <i>Hypertens Res</i> <b>40</b> , 423-428 (2017).

599 600	40	Yndestad, A. <i>et al.</i> Role of inflammation in the progression of heart failure. <i>Curr Cardiol Rep</i> <b>9</b> 236-241 (2007)
601	41	Dick, S. A. & Epelman, S. Chronic Heart Failure and Inflammation: What Do We Really
602		Know? Circ Res 119, 159-176 (2016).
603	42	Bloxham, C. J., Foster, S. R. & Thomas, W. G. A Bitter Taste in Your Heart. Front Physiol
604		<b>11</b> , 431 (2020).
605	43	Wang, Q. et al. Rare variant contribution to human disease in 281,104 UK Biobank exomes.
606		<i>Nature</i> <b>597</b> , 527-532 (2021).
607	44	Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through
608		exome sequencing of the UK Biobank. <i>Nat Genet</i> 53, 942-948 (2021).
609	45	Van Hout, C. V. <i>et al.</i> Exome sequencing and characterization of 49,960 individuals in the UK
610 611	16	Biobank. Nature <b>580</b> , 749-750 (2020).
612	40	Missense Variants Am I Hum Ganat 99, 877-885 (2016)
613	47	Travnelis I et al Ontimizing genomic medicine in enilensy through a gene-customized
614	• /	approach to missense variant interpretation. Genome Res 27, 1715-1729 (2017).
615	48	Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in
616		141,456 humans. Nature 581, 434-443 (2020).
617	49	Pedersen, B. S. & Quinlan, A. R. Who's Who? Detecting and Resolving Sample Anomalies in
618		Human DNA Sequencing Studies with Peddy. American Journal of Human Genetics 100,
619		406-413 (2017).
620	50	Jun, G. et al. Detecting and estimating contamination of human DNA samples in sequencing
621		and array-based genotype data. American Journal of Human Genetics 91, 839-848 (2012).
622	51	Manichaikul, A. <i>et al.</i> Robust relationship inference in genome-wide association studies.
623	50	Bioinformatics (Oxford, England) 26, 2867-2873 (2010).
624	52	Carss, K. J. <i>et al.</i> Spontaneous Coronary Artery Dissection: Insights on Rare Genetic
625	52	Variation From Genome Sequencing. Circ Genom Precis Med 13, e003030 (2020). Hoinza, G. & Schemmer, M. A solution to the problem of monotone likelihood in Cox.
620 627	55	regression <i>Biometrics</i> 57 114-119 (2001)
628	54	Dunkler D Ploner M Schemper M & Heinze G Weighted Cox Regression Using the R
629	51	Package coxphw. J. Stat. Soft. 84, 1-26 (2018).
630	55	Liu, Y. <i>et al.</i> RNA-Seq identifies novel myocardial gene expression signatures of heart failure.
631		Genomics 105, 83-89 (2015).
632	56	Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions
633		of gene lists (2019 update). Nucleic Acids Research 47, W191-W198 (2019).
634	57	Brown, K. K. et al. Approaches to target tractability assessment - a practical perspective.
635		Medchemcomm 9, 606-613 (2018).
636	58	Deelen, P. et al. Improving the diagnostic yield of exome- sequencing by predicting gene-
637		phenotype associations using large-scale gene expression analysis. Nat Commun 10, 2837
638	- 0	(2019).
639	59	Cochran, W. G. The Combination of Estimates from Different Experiments. <i>Biometrics</i> 10, 101, 100, (105.1)
640	(0	101-129 (1954).
641	60	Higgins, J. P. I. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat Med
042 642	61	<b>21</b> , 1559-1558 (2002). Commi E <i>et al.</i> The aPie concert conomics portal: an onen plotform for exploring
043 644	01	multidimensional cancer genomics data <i>Cancer Discov</i> <b>2</b> 401-404 (2012)
645	62	Gao L et al. Integrative analysis of complex cancer genomics and clinical profiles using the
646	02	cBioPortal. Sci Signal 6, pl1 (2013).
0.10		22102 crain sor orginar o, pri (2010).
647		

Chazara et al.

# 649 Acknowledgments

650

651 We thank the participants and investigators of the UK Biobank study who made this work possible 652 (Resource Application Number 26041). We thank the UKB Exome Sequencing Consortium (UKB-653 ESC) members AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, 654 Pfizer, Regeneron and Takeda for funding the generation of the data, and the Regeneron Genetics 655 Center for completing the sequencing and initial quality control of the exome sequencing data. We 656 acknowledge the AstraZeneca Centre for Genomics Research Analytics and Informatics team for 657 processing and analysis of sequencing data. We thank all the study participants for contributing to this 658 effort and the CHARM and CORONA co-investigators. Finally, we thank Sri Deevi and Dorota 659 Matelska from the AstraZeneca Centre for Genomics Research for their support, for which we are 660 grateful. M.-P.D. is funded by the Canada Research Chairs Program and by the Health Collaboration 661 Acceleration Fund from the Government of Quebec. J.C.T. holds the Canada Research Chair in 662 personalized and translational medicine and the Université de Montréal endowed research chair in 663 atherosclerosis. 664

665

## 666 Author Contributions Statement

667

O.C., M-P.D., C.H., J-C.T., D.S.P. and K.C. conceived and designed the study. O.C., Q.W., L.M. and
A.W. performed the statistical and computational analyses. M-P.D., D.V., D.S.P. and K.C. supervised
the analyses. M-P.D., C.B.G, J.K., C.H., J-C.T., D.S.P. and K.C. participated in the acquisition of the
data. O.C., M-P.D., Q.W., L.M., D.V., A.W., Q-D.W., K.M.H., C.B.G, J.K., C.H., J-C.T., D.S.P. and
K.C. participated in the data interpretation. O.C., M-P.D., L.M., A.W., J-C.T., D.S.P. and K.C. wrote
the initial draft of the manuscript. All authors contributed to the revision of the first draft. All authors
approved the final version of the manuscript.

675 676

## 677 Competing Interests Statement

678

O.C., Q.W., L.M., D.V., A.W., Q.-D.W., K.M.H., C.H., D.S.P. and K.C. report personal fees from
AstraZeneca during the conduct of the study. Q.W., C.H. and D.S.P. are stockholders of AstraZeneca.
M.-P.D. reports personal fees and minor equity interest from Dalcor, other from AstraZeneca,
GlaxoSmithKline, Pfizer, Servier, Sanofi. J.C.T. reports a grant from AstraZeneca for the conduct of
the study; other grants from AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis,

684 Pfizer and RegenXBio; honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals,

#### Chazara et al.

685 Pendopharm and Pfizer; minor equity interest in DalCor Pharmaceuticals. J.C.T. is author on patents 686 "Methods of treating a coronavirus infection using Colchicine and Methods of treating a coronavirus 687 infection using Colchicine" pending and a patent "Early administration of low-dose colchicine after 688 myocardial infarction" pending assigned to the Montreal Heart Institute. M.-P.D. and J.C.T. are 689 authors on a patent "Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk 690 of Cardiovascular Events" issued to Dalcor, no royalties received, a patent "Genetic Markers for 691 Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent" issued to 692 Dalcor, no royalties received, and a patent "Methods for using low dose colchicine after myocardial 693 infarction", assigned to the Montreal Heart Institute. J.C.T. has waived his rights in colchicine patents 694 and does not stand to gain financially. C.B.G. reports personal fees from AbbVie, Bayer, Boston 695 Scientific, CeleCor, Correvio, Espero BioPharma, Medscape, Medtronic, Merck, National Institutes of 696 Health, Novo Nordisk, Rhoshan and Roche; grants from Akros, Apple, AstraZeneca, Daiichi Sankyo, 697 US Food and Drug Administration, GlaxoSmithKline and Medtronic Foundation; grants and personal 698 fees from Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Pfizer; and other 699 support from Duke Clinical Research Institute outside the submitted work. Funding for the exome 700 sequencing in the CHARM, CORONA and UK Biobank studies was provided fully or partially by 701 AstraZeneca.

Chazara et al.

# 703 Tables

# 705 **Table 1. Characteristics of patients included in the analysis.**

<sup>706</sup> 

	CHARM	CORONA	UK Biobank	Total
Number of patients, n	2,672	2,776	2,641	8,089
Age, mean ± SD	$66.5\pm10.9$	$72.5\pm6.9$	$61.9\pm6.1$	$67.1\pm9.3$
Men, n (%)	1,788 (66.9%)	2,139 (77.1%)	2,016 (76.3%)	5,943 (73.5%)
Treatment (interventional)	1,346 (50.4%)	1,391 (50.1%)	NA	NA
LVEF, mean ± SD	$0.38\pm0.15$	$0.31\pm0.06$	NA*	$0.35\pm0.12$
BMI (kg/m <sup>2</sup> ), mean ± SD	$28.6\pm5.8$	$27.4\pm4.5$	$30.2\pm5.6$	$28.7\pm5.4$
Current smoker, n (%)	384 (14.4%)	250 (9.0%)	334 (12.6%)	968 (12.0%)
Myocardial infarction, n (%)	1,490 (55.8%)	1,692 (61.0%)	1,312 (49.7%)	4,494 (55.6%)
Diabetes, n (%)	768 (28.7%)	763 (27.5%)	850 (32.2%)	2,381 (29.4%)
Atrial fibrillation, n (%)	801 (30.0%)	1,931 (69.6%)	1,260 (47.7%)	3,992 (49.4%)
CV death	504 (18.9%)	358 (12.9%)	466 (17.6%)	1,328 (16.4%)
CV death and/or HF hospitalisation	895 (33.5%)	843 (30.4%)	713 (27.0%)	2,451 (30.3%)

707

708 \*LVEF only available for 66 UK Biobank individuals. BMI: body mass index; CV: cardiovascular; HF: heart

failure; LVEF: left ventricular ejection fraction; N: number of patients; NA: not available; SD: standard

710 deviation.

<sup>704</sup> 

Table 2. Gene-based collapsing meta-analysis results for 'time to cardiovascular death' (top) or 'time to cardiovascular death and/or hospitalisation for heart failure' (bottom).

Gene	Genetic model*	N (studies)	Р	HR (95% CI)	SE	Q	I <sup>2</sup> **	Total	CHARM	CORONA	UK Biobank	
								N (carriers)	P (carriers) <sup>†</sup>	P (carriers) <sup>†</sup>	P (carriers) <sup>†</sup>	
Time to ca	rdiovascular death											
FAM221A	Flexible non-synonymous	3	3.85E-08	5.14 (2.87, 9.21)	1.35	0.20	38.02	25	1.38E-02 (8)	6.48E-01 (7)	1.77E-04 (10)	
CUTC	Flexible non-synonymous (MTR)	3	3.90E-08	5.13 (2.85, 9.13)	1.35	0.50	0	19	1.67E-02 (5)	1.70E-01 (6)	6.32E-04 (8)	
IFIT5	Flexible damaging	3	4.77E-08	4.77 (2.72, 8.33)	1.34	0.36	2.20	24	2.47E-02 (8)	9.19E-04 (8)	5.91E-02 (8)	
STIMATE	Flexible non-synonymous	3	7.68E-08	4.39 (2.56, 7.52)	1.32	0.50	0	25	4.28E-02 (6)	8.69E-04 (10)	4.28E-02 (9)	
TAS2R20	Flexible non-synonymous,	3	2.57E-07	3.93 (2.34, 6.63)	1.31	0.26	25.85	34	3.44E-02 (10)	1.54E-04 (16)	7.69E-01 (8)	
	Flexible non-synonymous (MTR)											
Time to cardiovascular death and/or hospitalisation for heart failure												
CALB2	Flexible non-synonymous	3	4.82E-09	4.47 (2.71, 7.39)	1.30	0.20	37.83	21	6.94E-02 (8)	3.05E-02 (6)	1.07E-04 (7)	
BLK	Ultra-rare	2	5.46E-08	6.88 (3.43, 13.84)	1.43	0.86	0	10	NA	1.49E-03 (5)	7.67E-03 (5)	

Fixed-effects meta-analysis p-value< $2.7 \times 10^{-7}$ ; \*genetic model details in **Supplementary Table 14**; \*\*filtered on I<sup>2</sup> $\leq$ 40; <sup>†</sup>filtered on carrier count  $\geq$ 5 from input (a posteriori); P: Fixed-effects meta-analysis p-value; HR: hazard ratio; CI: confidence interval; SE: standard error; Q: Cochran's Q p-value testing for heterogeneity<sup>59</sup>; I<sup>2</sup>: percentage of variation across studies that is due to heterogeneity rather than chance<sup>60</sup>; CHARM/CORON/UK Biobank P: coxphf p-value for CHARM/CORONA/UK Biobank; MTR, missense tolerance ratio. Table 3. Summary of supporting genetic evidence from (A) Cardiovascular Disease Knowledge Portal and (B) published GWAS on several cardiovascular outcomes.

	A) Cardiovascular Disease Knowledge Portal										B) Published GWAS data											
Gene	Cardiovascular			Lipids			Anthropometric		Heart failure		Non-ischemic cardiomyopathy		Atrial fibrillation		Any cardiovascular disease		Myocardial infarction		Hypertension			
	Trait	Р	beta	Trait	Р	beta	Trait	Р	beta	Р	beta	Р	beta	Р	beta	Р	beta	Р	beta	Р	beta	
FAM221A							Height	3.52E-76	▼-0.0007	1.29E-04	▲ 1.06	5.03E-02	▲ 1.07	8.76E-05	▲ 5.82	1.71E-04	▲ 1.04	9.32E-03	▲ 3.38	4.57E-03	▲ 1.02	
CUTC	Heart rate	2.73E-09	▼-0.100				Height	1.80E-28	<b>▼</b> -0.0003	1.67E-03	▲ 1.86	8.07E-03	▼ 0.85	1.79E-04	▲ 1.52	6.82E-03	▼ 0.95	1.25E-02	▲ 13.52	2.20E-05	▼ 0.95	
IFIT5	Diastolic blood pressure	1.74E-08	▲ 0.011							2.72E-03	▲ 2.59	2.37E-03	▼ 0.81	1.76E-03	▲ 1.20	2.32E-06	▲ 1.02	1.62E-02	▼ 0.08	1.38E-04	▲ 1.23	
STIMATE	Pulse pressure	1.03E-13	▲ 0.007	TGs	8.92E-19	▼ -0.023	Height	8.09E-83	▼-0.0006	2.08E-03	▲ 1.04	1.27E-04	▲ 1.20	5.00E-03	▲ 2.16	1.00E-07	▼ 0.95	7.35E-04	▲ 1.17	6.26E-06	▲ 1.02	
TAS2R20										2.21E-03	▲ 1.07	1.77E-03	▲ 1.50	4.28E-03	▲ 1.73	6.80E-03	▼ 0.99	2.74E-02	▼ 0.86	4.19E-03	▼ 0.86	
CALB2	Ascending aorta diameter	2.90E-34	▼-0.190	LDL-C	2.57E-292	▲ 0.033	BMI	2.42E-22	▼-0.020	1.34E-03	▲ 1.04	2.22E-03	▼ 0.84	8.40E-04	▲ 1.37	1.22E-04	▼ 0.96	3.81E-02	▼ 0.85	3.20E-06	▼ 0.96	
BLK	Systolic blood pressure	2.07E-22	▼-0.013	TGs	9.71E-30	▲ 0.027	BMI	1.20E-25	▼-0.012	7.22E-04	▼ 0.94	2.72E-03	▼ 0.85	6.31E-03	▲ 1.29	1.84E-03	▲ 1.02	1.27E-03	▲ 48.34	6.14E-05	▲ 1.05	

From the Cardiovascular Disease Knowledge Portal, we retrieved the most significant common-variant associations ( $p \le 5x10^{-8}$ ) for cardiovascular, lipid and anthropometric traits at each gene region, clumped by linkage disequilibrium.

Chazara et al.

# **Figures**

Figure 1. Study design.



Chazara et al.

Figure 2. Forest plot of the significant results ( $p<2.7x10^{-7}$ ) from the meta-analysis of CHARM, CORONA and the UK Biobank for time to cardiovascular death (A-E) and time to cardiovascular death and/or hospitalisation for heart failure (F-G).



**A**, *FAM221A* in the flexible non-synonymous model; **B**, *CUTC* in the flexible non-synonymous (MTR) model; **C**, *IFIT5* in the flexible damaging model; **D**, *STIMATE* in the flexible non-synonymous model; **E**, *TAS2R20* in the flexible non-synonymous and/or in flexible non-synonymous (MTR) model; **F**, *CALB2* in the flexible non-synonymous model; **G**, *BLK* in the ultra-rare model.

Chazara et al.

Figure 3. Lollipop plots depicting the individual variants across the candidate genes from the meta-analysis of time to cardiovascular death (A-E) and time to cardiovascular death and/or hospitalisation for heart failure (F-G).



Variants in patients with event at the top and no-event at the bottom. More details on variants identified in heart failure patients with detrimental events in **Supplementary Table 4**. **A**, *FAM221A* in the flexible non-synonymous model (ENST00000344962); **B**, *CUTC* in the flexible non-synonymous (MTR) model (ENST00000370476); **C**, *IFIT5* in the flexible damaging model (ENST00000371795); **D**, *STIMATE* in the flexible non-synonymous model (ENST00000355083); **E**, *TAS2R20* in the flexible non-synonymous and/or in flexible non-synonymous (MTR) model (ENST00000538986); **F**, *CALB2* in the flexible non-synonymous model (ENST00000302628); **G**, *BLK* in the ultra-rare model (ENST00000259089). Lollipop plots were produced with the cbioportal mutation mapper tool<sup>61,62</sup>.

Chazara et al.

Figure 4. Heatmaps showing the differential expression in cardiac tissue from patients with heart failure vs controls of candidate genes from the meta-analysis of time to cardiovascular death and/or hospitalisation for heart failure. The heatmaps show A, magnitude of change (logFC; red: upregulated in HF vs control; blue: downregulated in HF vs control), and B, significance ( $-\log_{10}(adj. p-value)$ ). ns: not significant (adj. p>0.05), na: not assessed.



